Literature DB >> 31886867

Molecular Subtypes and Genomic Profile of Primary Central Nervous System Lymphoma.

Csaba Bödör1, Donát Alpár1, Dóra Marosvári1, Bence Galik2, Hajnalka Rajnai1, Bence Bátai1, Ákos Nagy1, Béla Kajtár3, Adrienn Burján3, Beáta Deák4, Tamás Schneider4, Hussain Alizadeh5, András Matolcsy1, Sebastian Brandner6, James Storhoff7, Ning Chen7, Mingdong Liu7, Nadeem Ghali8, Irén Csala9, Attila G Bagó10, Attila Gyenesei2, Lilla Reiniger1,11.   

Abstract

Primary central nervous system lymphomas (PCNSL) are aggressive non-Hodgkin lymphomas affecting the central nervous system (CNS). Although immunophenotyping studies suggested an uniform activated B-cell (ABC) origin, more recently a spectrum of ABC and germinal center B-cell (GC) cases has been proposed, with the molecular subtypes of PCNSL still being a matter of debate. With the emergence of novel therapies demonstrating different efficacy between the ABC and GC patient groups, precise assignment of molecular subtype is becoming indispensable. To determine the molecular subtype of 77 PCNSL and 17 secondary CNS lymphoma patients, we used the NanoString Lymphoma Subtyping Test (LST), a gene expression-based assay representing a more accurate technique of subtyping compared with standard immunohistochemical (IHC) algorithms. Mutational landscapes of 14 target genes were determined using ultra-deep next-generation sequencing. Using the LST-assay, a significantly lower proportion (80% vs 95%) of PCNSL cases displayed ABC phenotype compared with the IHC-based characterization. The most frequently mutated genes included MYD88, PIM1, and KMT2D. In summary, we successfully applied the LST-assay for molecular classification of PCNSL, reporting higher proportion of cases with GC phenotype compared with IHC analyses, leading to a more precise patient stratification potentially applicable in the diagnostic algorithm of PCNSL.
© 2019 American Association of Neuropathologists, Inc. All rights reserved.

Entities:  

Keywords:  Brain lymphoma; Molecular subtype; Mutation profiling; Primary central nervous system lymphomas (PCNSL)

Mesh:

Year:  2020        PMID: 31886867     DOI: 10.1093/jnen/nlz125

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  10 in total

1.  Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL.

Authors:  Wyndham H Wilson; George W Wright; Da Wei Huang; Brendan Hodkinson; Sriram Balasubramanian; Yue Fan; Jessica Vermeulen; Martin Shreeve; Louis M Staudt
Journal:  Cancer Cell       Date:  2021-11-04       Impact factor: 31.743

Review 2.  [Lymphoma of the eye and its adnexa : Modern pathological diagnostics and systemic treatment].

Authors:  Falko Fend; Irina Bonzheim; Vinodh Kakkassery; Ludwig M Heindl; Gerald Illerhaus
Journal:  Ophthalmologie       Date:  2022-05-23

3.  The genomic and transcriptional landscape of primary central nervous system lymphoma.

Authors:  Josefine Radke; Naveed Ishaque; Randi Koll; Zuguang Gu; Elisa Schumann; Lina Sieverling; Sebastian Uhrig; Daniel Hübschmann; Umut H Toprak; Cristina López; Xavier Pastor Hostench; Simone Borgoni; Dilafruz Juraeva; Fabienne Pritsch; Nagarajan Paramasivam; Gnana Prakash Balasubramanian; Matthias Schlesner; Shashwat Sahay; Marc Weniger; Debora Pehl; Helena Radbruch; Anja Osterloh; Agnieszka Korfel; Martin Misch; Julia Onken; Katharina Faust; Peter Vajkoczy; Dag Moskopp; Yawen Wang; Andreas Jödicke; Lorenz Trümper; Ioannis Anagnostopoulos; Dido Lenze; Ralf Küppers; Michael Hummel; Clemens A Schmitt; Otmar D Wiestler; Stephan Wolf; Andreas Unterberg; Roland Eils; Christel Herold-Mende; Benedikt Brors; Reiner Siebert; Stefan Wiemann; Frank L Heppner
Journal:  Nat Commun       Date:  2022-05-10       Impact factor: 17.694

4.  Whole-Genome/Exome Sequencing Uncovers Mutations and Copy Number Variations in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.

Authors:  Qiong Zhu; Jianchao Wang; Wenfang Zhang; Weifeng Zhu; Zaizeng Wu; Yanping Chen; Musheng Chen; Limei Zheng; Jianqing Tang; Sheng Zhang; Di Wang; Xingfu Wang; Gang Chen
Journal:  Front Genet       Date:  2022-05-12       Impact factor: 4.772

5.  EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity.

Authors:  M K Gandhi; T Hoang; S C Law; S Brosda; K O'Rourke; J W D Tobin; F Vari; V Murigneux; L Fink; J Gunawardana; C Gould; H Oey; K Bednarska; S Delecluse; R U Trappe; L Merida de Long; M B Sabdia; G Bhagat; G Hapgood; E Blyth; L Clancy; J Wight; E Hawkes; L M Rimsza; A Maguire; K Bojarczuk; B Chapuy; C Keane
Journal:  Blood       Date:  2021-03-18       Impact factor: 22.113

6.  Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype.

Authors:  Ruben A L de Groen; Ronald van Eijk; Stefan Böhringer; Tom van Wezel; Richard Raghoo; Dina Ruano; Patty M Jansen; Inge Briaire-de Bruijn; Fleur A de Groot; Karin Kleiverda; Liane Te Boome; Valeska Terpstra; Henriette Levenga; Alina Nicolae; Eduardus F M Posthuma; Isabelle Focke-Snieders; Lizan Hardi; Wietske C E den Hartog; Lara H Bohmer; Pancras C W Hogendoorn; Anke van den Berg; Arjan Diepstra; Marcel Nijland; Pieternella J Lugtenburg; Marie José Kersten; Steven T Pals; Hendrik Veelken; Judith V M G Bovée; Arjen H G Cleven; Joost S P Vermaat
Journal:  Blood Adv       Date:  2021-10-12

Review 7.  Update on Novel Therapeutics for Primary CNS Lymphoma.

Authors:  Lauren R Schaff; Christian Grommes
Journal:  Cancers (Basel)       Date:  2021-10-26       Impact factor: 6.639

8.  PIM1 and CD79B Mutation Status Impacts the Outcome of Primary Diffuse Large B-Cell Lymphoma of the CNS.

Authors:  Jihao Zhou; Min Zuo; Lifeng Li; Fang Li; Peng Ke; Yangying Zhou; Yaping Xu; Xuan Gao; Yanfang Guan; Xuefeng Xia; Xin Yi; Xinyou Zhang; Yuhua Huang
Journal:  Front Oncol       Date:  2022-02-09       Impact factor: 6.244

9.  Cell-of-origin classification using the Hans and Lymph2Cx algorithms in primary cutaneous large B-cell lymphomas.

Authors:  Anne M R Schrader; Ruben A L de Groen; Rein Willemze; Patty M Jansen; Koen D Quint; Tom van Wezel; Ronald van Eijk; Dina Ruano; Cornelis P Tensen; Esther Hauben; F J S H Woei-A-Jin; Anne M Busschots; Anke van den Berg; Arjan Diepstra; Maarten H Vermeer; Joost S P Vermaat
Journal:  Virchows Arch       Date:  2022-01-14       Impact factor: 4.535

10.  The molecular hallmarks of primary and secondary vitreoretinal lymphoma.

Authors:  Irina Bonzheim; Philip Sander; Julia Salmerón-Villalobos; Daniela Süsskind; Peter Szurman; Florian Gekeler; Martin S Spitzer; Julia Steinhilber; Esther Kohler; Melanie Büssgen; Jens Schittenhelm; Itziar Salaverria; Elias Campo; Sarah E Coupland; Leticia Quintanilla-Martinez; Falko Fend
Journal:  Blood Adv       Date:  2022-03-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.